Mullen, Douglas


Bachelor of Science in Engineering
Duke University, 2005

Doctor of Philosophy

University of Michigan, 2010

About this team member

Douglas Mullen received a Bachelor’s of Science in Engineering from Duke University in 2005. At Duke he was a Pratt Undergraduate Research Fellow and a member of the Center for Biologically Inspired Materials and Material Systems. He began his graduate career in the Macromolecular Science and Engineering Program at the University of Michigan in 2005 and became a member of the Banaszak Holl research group and the Michigan Nanotechnology Institute for Medicine and Biological Sciences. In 2007 Doug received a Master’s of Science in Engineering from the University of Michigan’s Program in Macromolecular Science and Engineering and in 2009 he completed the MBA Essentials and Entrepreneurship Program at Michigan’s Ross School of Business. He completed the Doctoral Program in the Macromolecular Science and Engineering Program in 2010.   His thesis work involved the development of targeted chemotherapeutic agents. He received several awards including the Raymond C. Gaugler Award in Materials Science and Engineering at Duke, the Rackham Regents Fellowship at the University of Michigan, an award for Excellence in Graduate Polymer Research from the American Chemical Society, and the National Starch and Chemical Award from the Macromolecular Science and Engineering Program at the University of Michigan.  A review article describing much of Doug’s graduate research was published as the cover article in Account of Chemical Research.

Doug spent a year as a Medical Innovation fellow at the University of Michigan’s medical school and then worked at MNIMBS as our technology translation specialist.

Doug is currently Senior Analyst at Fletcher Spaght, Inc, a venture capital fund investing in emerging growth high technology and healthcare companies in Boston, Massachusetts.  This firm provides strategy and financing assistance to new ventures, including start-up companies, risk capital investors and emerging technologies/growth enterprises within larger organizations.


  • Dendrimer-Based Nanoparticle Therapies: Can Uniform Multifunctional Therapeutics Be Made with Current Chemical Approaches? 2012
  • Best Practices for Purification and Characterization of PAMAM Dendrimer Macromolecules 2012 45 5316-5320
  • Acetonitrile Shortage: Use of isopropanol as an alternative elution system for ultrahigh performance liquid chromatograph Analytical Methods 2011 3 56-58.
  • Design, Synthesis, and Biological Functionality of a Dendrimer-based Modular Drug Delivery Platform Bioconjugate Chemistry 2011 22 679-689
  • Heterogeneous ligand-nanoparticle distributions: a major obstacle to scientific understanding and commercial translation Accounts of Chemical Research 2011 44 1135-1252
  • The Mechanism of Polyplexes Internalization into Cells: Testing the GM1/Caveolin-1-Mediated Lipid Raft Mediated Endocytosis Pathway Molecular Pharmaceutics 2010 7 267-279.
  • A Quantitative Assessment of Nanoparticle-Ligand Distributions: Implications for Targeted Drug and Imaging Delivery in Dendrimer Conjugates ACS Nano 2010 4 657-670.
  • Polycation-Induced Cell Membrane Permeability Does Not Enhance Cellular Uptake or Expression Efficiency of Delivered DNA Molecular Pharmaceutics 2010 7 870-883.
  • Solid State NMR Reveals the Hydrophobic-Core Location of Poly(amidoamine) Dendrimers in Biomembranes J. Am. Chem. Soc. 2010 132 8087-8097.
  • Effect of Mass Transport in the Synthesis of Partially Acetylated Dendrimer:  Implications for Functional Ligand-Nanoparticle Interactions Macromolecules 2010 43 6577-6587.
  • Isolation and Characterization of Dendrimers with Precise Numbers of Functional Groups Chemistry a European Journal 2010 10 10675-10678.
  • Origin of broad polydispersion in functionalized dendrimers and its effects on cancer-cell binding affinity Physical Review E 2010 82 36108
  • Stoichiometry and Structure of Poly(amidoamine) Dendrimer-Lipid Complexes ACS Nano 2009 3 1886-1896.
  • Cationic Nanoparticles Induce Nanoscale Disruption in Living Cell Plasma Membranes Journal of Physical Chemistry B 2009 113 11179-11185
  • The Role of Ganglioside GM1 in Cellular Internalization Mechanisms of Poly(amidoamine) Dendrimers Bioconjugate Chemistry 2009 20 1503-1513.
  • RGD Dendron Bodies: Synthetic Avidity Agents with Defined and Potentially Interchangeable Effector Sites That Can Substitute for Antibodies Bioconjugate Chemistry 2009 20 1853-1859.
  • Cationic Poly(amidoamine) Dendrimer Induces Lysosomal Apoptotic Pathway at Therapeutically Relevant Concentrations Biomacromolecules 2009 10 3207–3214.
  • Interaction of Poly(amidoamine) Dendrimers with Survanta Lung Surfactant:  The Importance of Lipid Domains Langmuir 2008 24 11003-11008
  • The Implications of Stochastic Synthesis for the Conjugation of Functional Groups to Nanoparticles Bioconjugate Chemistry 2008 19 1748-1752.